Live Breaking News & Updates on Hansc Lee

Stay updated with breaking news from Hansc lee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma. ....

United States , Hansc Lee , Department Of Lymphoma Myeloma , Myeloma Clinical Research , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center , The University Of Texas Md Anderson Cancer Center , Onclive Tv , Multiple Myeloma , Phase 2 Linker Mm1 Study Nct03761108 , Bcma Cd3 Directed Bispecific Antibody ,

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its. ....

United States , San Diego , Sikander Ailawadhi , Francesco Passamonti , Lisocabtagene Maraleucel , Guillaume Cartron , Ravi Vij , Maroof Hasan , Mark Kaplan , Rachid Baz , Hemophagocytic Lymphohistiocytosis , Danny Jeyaraju , Sheida Hayati , Susan Bal , Samit Hirawat , Franck Morschhauser , Bristol Myers Squibb , Lauren Peres , Sujit Sheth , Marc Hoffmann , Tracy Chow , Hansc Lee , Michael Wang , Esther Oliva , Leslie Andritsos , Michele Delforge ,

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.
....

United States , Hansc Lee , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Department Of Lymphoma Myeloma , Myeloma Clinical Research , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center ,

Linvoseltamab Shows High Response Rate, Manageable Toxicity for Pretreated Myeloma

The BCMA/CD3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma. ....

United States , Hansc Lee , University Of Texas Md Anderson Cancer Center , Asco Annual Meeting ,